Mild Cognitive Impairment (MCI). Mild cognitive impairment, so stated
Conditions
Interventions
Intervention 1: Intervention group: Pack of 30 oral capsules of rivastigmine (hydrogen titrate) 3 mg Hakim Pharmaceutical Company twice a day. Intervention 2: Control group: Pack of 30 oral capsules o
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Mild cognitive impairment diagnosis on Functional Assessment Staging Test (FAST)=3 Age more than 40 Third grade education Mini-mental state examination between 24 to 30
Exclusion criteria
Exclusion criteria: Psychiatric disorder history Untreated depression Vitamin b12 deficiency Uncontrol hypothyroidism Drug abuse during 6 month ago Seizure history Major neurologic disorder Stroke Cholinesterase inhibitor administration during 6 month ago Other disease interfere with decision making Heart block, bradycardia (heart rate<60) Gastrointestinal bleeding during 6 month ago Pregnancy and lactation Rivastigmine allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect on decision making. Timepoint: 3 months from the start of the intervention. Method of measurement: CANTAB test including CGT (Gambling Cambridge Test) ?IST (Information Task Sampling) ? SST (Stop Signal Task). | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event evaluation. Timepoint: Every two weeks. Method of measurement: Ask questions of the patient and record information. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSetayesh Sadeghi
Tehran University of Medical Sciences
Outcome results
None listed